204 related articles for article (PubMed ID: 36551989)
1. Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience.
Levra S; Guida G; Sprio AE; Crosa F; Ghio PC; Bertolini F; Carriero V; Albera C; Ricciardolo FLM
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551989
[TBL] [Abstract][Full Text] [Related]
2. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
[TBL] [Abstract][Full Text] [Related]
3. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
4. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
5. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
6. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.
Huh JY; Lee JH; Song JW
Front Pharmacol; 2023; 14():1301923. PubMed ID: 38192410
[No Abstract] [Full Text] [Related]
8. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data.
Khan MA; Sherbini N; Alyami S; Al-Harbi A; Al-Ghamdi M; Alrajhi S; Rajendram R; Al-Jahdali H
Ann Thorac Med; 2023; 18(1):45-51. PubMed ID: 36968327
[TBL] [Abstract][Full Text] [Related]
9. Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Tsurumaki H; Shin Y; Wakamatsu I; Kasahara N; Yamaguchi K; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Respir Investig; 2024 May; 62(3):388-394. PubMed ID: 38460356
[TBL] [Abstract][Full Text] [Related]
10. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.
Toellner H; Hughes G; Beswick W; Crooks MG; Donaldson C; Forrest I; Hart SP; Leonard C; Major M; Simpson AJ; Chaudhuri N
Clin Transl Med; 2017 Nov; 6(1):41. PubMed ID: 29101500
[TBL] [Abstract][Full Text] [Related]
11.
Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study.
Vianello A; Salton F; Molena B; Turato C; Graziani ML; Braccioni F; Frassani V; Sella D; Pretto P; Paladini L; Sukthi A; Confalonieri M
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32033147
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
[TBL] [Abstract][Full Text] [Related]
17. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
18. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
Dempsey TM; Payne S; Sangaralingham L; Yao X; Shah ND; Limper AH
Ann Am Thorac Soc; 2021 Jul; 18(7):1121-1128. PubMed ID: 33465323
[No Abstract] [Full Text] [Related]
19. Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Hughes G; Toellner H; Morris H; Leonard C; Chaudhuri N
J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27598213
[TBL] [Abstract][Full Text] [Related]
20. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
